Annexon FY2026 EPS Estimate Boosted by Cantor Fitzgerald

Annexon, Inc. (NASDAQ:ANNX) – Equities research analysts at Cantor Fitzgerald lifted their FY2026 earnings per share (EPS) estimates for shares of Annexon in a research report issued on Tuesday, November 25th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will earn ($1.18) per share for the year, up from their prior estimate of ($1.20). The consensus estimate for Annexon’s current full-year earnings is ($0.96) per share.

A number of other research firms also recently issued reports on ANNX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Annexon in a research note on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and issued a $14.00 price objective on shares of Annexon in a research note on Friday, August 15th. Zacks Research raised Annexon from a “strong sell” rating to a “hold” rating in a research report on Monday, August 18th. Finally, Wells Fargo & Company lifted their price target on Annexon from $14.00 to $27.00 and gave the company an “overweight” rating in a report on Wednesday, November 19th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $17.33.

Annexon Stock Performance

NASDAQ ANNX opened at $4.32 on Thursday. Annexon has a one year low of $1.28 and a one year high of $5.66. The company has a market capitalization of $516.81 million, a price-to-earnings ratio of -3.35 and a beta of 1.28. The company’s 50-day simple moving average is $3.20 and its two-hundred day simple moving average is $2.65.

Annexon (NASDAQ:ANNX) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.03).

Insider Activity at Annexon

In other news, Director Muneer A. Satter bought 500,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 19th. The stock was bought at an average price of $3.94 per share, with a total value of $1,970,000.00. Following the completion of the transaction, the director directly owned 8,906,024 shares of the company’s stock, valued at approximately $35,089,734.56. The trade was a 5.95% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders have purchased 1,830,843 shares of company stock worth $7,091,379. Insiders own 11.87% of the company’s stock.

Hedge Funds Weigh In On Annexon

A number of large investors have recently made changes to their positions in the business. Matauro LLC purchased a new stake in shares of Annexon during the 2nd quarter valued at $27,000. Vanguard Personalized Indexing Management LLC purchased a new stake in Annexon in the second quarter valued at about $29,000. 49 Wealth Management LLC purchased a new stake in Annexon in the second quarter valued at about $29,000. CIBC Bancorp USA Inc. acquired a new stake in Annexon in the third quarter worth about $31,000. Finally, Engineers Gate Manager LP purchased a new stake in shares of Annexon during the second quarter worth about $32,000.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.